The Hidden Cause of Many Strokes
Cerebral small vessel disease (CSVD) affects the tiny blood vessels deep inside the brain. When these vessels are damaged, they can no longer deliver enough blood and oxygen to the surrounding brain tissue. Over time, white matter — the communication wiring of the brain — begins to deteriorate. This shows up on brain scans as bright white patches called white matter hyperintensities.
CSVD is responsible for about 25 percent of all strokes and is a major contributor to vascular dementia (memory and thinking problems caused by poor blood flow). Yet treatment options remain limited. Most people are told to control their blood pressure and hope for the best.
What We Tried Before, and Why It Wasn't Enough
Standard care for CSVD focuses on managing risk factors: blood pressure, cholesterol, blood sugar, and not smoking. These steps matter, but they do little to restore blood flow to already-damaged brain tissue.
But here's the twist: a class of drugs best known for treating erectile dysfunction and pulmonary hypertension — PDE5 inhibitors, which include sildenafil (Viagra) and tadalafil (Cialis) — may work directly on the tiny blood vessels in the brain. Laboratory and animal studies had already suggested these drugs could improve blood vessel function in the brain. This new meta-analysis is the first to pull together human trial data to see whether that promise holds up.
How PDE5 Inhibitors Work in the Brain
PDE5 inhibitors work like a traffic signal for blood vessels. Normally, a molecule called PDE5 acts as a brake, stopping blood vessels from relaxing and widening. These drugs block that brake, allowing vessels to dilate and let more blood through.
In the brain, better blood flow means more oxygen reaching the tissue around damaged white matter. Think of it like opening a partially clogged garden hose — the water pressure improves even if the hose itself isn't fully repaired. In CSVD, where blood flow is reduced but the vessels aren't completely blocked, this mechanism could meaningfully help.
What This Analysis Looked At
Researchers searched four major medical databases for all randomized controlled trials (studies where patients were randomly assigned to drug or placebo) of sildenafil or tadalafil in adults with CSVD, covering research published between 1990 and October 2025. Four studies met the criteria, involving 236 patients total. Researchers pooled the data using statistical methods designed to account for differences between studies.
PDE5 inhibitors significantly increased blood flow in the white matter hyperintensity regions of the brain — the exact areas most affected by CSVD. The improvement was modest but statistically meaningful: about 1.3 milliliters of blood per 100 grams of brain tissue per minute more than placebo. For reference, even small improvements in blood flow to oxygen-starved tissue can matter clinically.
The drugs also produced a small but consistent reduction in diastolic blood pressure (the lower number in a blood pressure reading) of about 4.7 mmHg, which could offer an added benefit for people with CSVD, where high blood pressure is a major driver of damage. Effects on overall cerebral blood flow velocity and cognitive test scores were not statistically significant across the pooled data — meaning the memory benefits, if any, remain unclear.
This doesn't mean these drugs should be taken for brain protection without a doctor's guidance — they carry real side effects and drug interactions.
Why This Direction Makes Sense
The researchers note that PDE5 inhibitors fit into a broader effort to find drugs that target the underlying blood vessel dysfunction in CSVD, rather than just its risk factors. The fact that these are already approved, widely used, and well-understood drugs makes this research path particularly appealing. If larger trials confirm the benefit, repurposing existing medications would be far faster and cheaper than developing entirely new ones.
PDE5 inhibitors are not currently approved or recommended for CSVD treatment. If you or a loved one has been diagnosed with CSVD, small vessel disease, or white matter changes on a brain scan, do not start or stop any medication based on this review. Talk to your neurologist about what treatment options are appropriate and whether any clinical trials in this area might be open to you.
Limitations to Keep in Mind
Only four trials were included, with a combined total of 236 patients. That is a very small evidence base for a condition that affects millions. The studies varied in how they defined CSVD and measured outcomes, making direct comparisons challenging. Cognitive outcomes — the ones patients care most about — did not show significant improvement in the pooled analysis, which is a key uncertainty. These results are promising, not definitive.
Larger, longer-term randomized controlled trials are the critical next step. Researchers need to test whether improved blood flow translates into real cognitive benefits — fewer memory problems, slower decline, better daily function — over months and years rather than weeks. The field is also working to identify which patients with CSVD are most likely to respond to this approach, since the disease affects people differently. If those trials succeed, PDE5 inhibitors could represent a meaningful new option for a condition that currently has very few.
